Posts tagged: trial
Preliminary results from Remedy Pharmaceuticals’ RP-1127 Phase 2 trial on stroke
Each year, over 700,000 people in the United States suffer a stroke. For most, medical science can do very little. Some will die; a number will suffer debilitating aftereffects. Now, preliminary results of a Phase 2 clinical trial using Remedy Pharmaceuticals' new drug, RP-1127, presented at the 2012 International Stroke ...
Orexigen reaches SPA agreement for Contrave outcomes trial with FDA
Orexigen Therapeutics, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for the Contrave outcomes trial.
Positive clinical results from randomized trial of InspireMD’s MGuard in STEMI patients
InspireMD, Inc., a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, announced positive clinical results from an investigator-sponsored controlled randomized trial conducted in Chile.
Positive updated results from Aeterna Zentaris’ AEZS-108 Phase 1 trial on CRPC
Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog.
Type 1 Diabetes Treatment Disappoints in Trial
By Serena Gordon HealthDay Reporter WEDNESDAY, Feb. 1 (HealthDay News) -- The latest trial of a drug called GAD-alum to treat type 1 diabetes failed to show any significant improvement in the common markers of the blood sugar disease. The researchers, however, ...
Reduced ‘Second Stroke’ After Aneurysm Rupture Shown In Trial Of Experimental Drug
An experimental drug, clazosentan, reduced the risk of blood vessel spasm in patients with a brain aneurysm, according to research presented at the American Stroke Association's International Stroke Conference 2012. In patients with a subarachnoid hemorrhage, even after the burst weak spot in the vessel is closed, irritation from the ...
NIAID, Aeras partner for Phase II clinical trial of TB vaccine
Aeras announces today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.
NIH to join multi-center clinical trial of new tuberculosis vaccine
Rockville, MD, USA Aeras announces today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch ...
NIH to join multi-center clinical trial of new tuberculosis vaccine
(Aeras) The National Institute of Allergy and Infectious Diseases, part of the United States National Institutes of Health, has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell. This is thee first time ...
Trial by fire: A landscape-scale experiment in restoring Ozark glades
A giant experiment is under way at the Tyson Research Center, Washington University in St. Louis' 2,000-acre outdoor laboratory for ecosystem studies.
Positive results from cisplatin plus radiation therapy trial on head and neck cancer
A select subgroup of advanced head and neck cancer patients treated with radiation therapy plus the chemotherapy drug cisplatin had more positive outcomes than patients treated with radiation therapy alone and continued to show positive results 10 years post-treatment, according to a study presented at the Multidisciplinary Head and Neck ...